Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT04341155

Dexamethasone for Cerebral Toxoplasmosis

Led by Universitas Padjadjaran · Updated on 2024-07-03

138

Participants Needed

1

Research Sites

219 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.

CONDITIONS

Official Title

Dexamethasone for Cerebral Toxoplasmosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or above
  • Clinical signs and symptoms compatible with cerebral toxoplasmosis
  • Positive HIV serology
  • Positive immunoglobulin G anti-toxoplasma titre
  • One or more mass lesions on neuroradiological imaging
  • Dexamethasone therapy taken for none or less than 3 days
  • Written informed consent from patient or close relatives if patient is unconscious
Not Eligible

You will not qualify if you...

  • Anti-toxoplasmosis treatment taken for more than 5 days before recruitment
  • Hypersensitivity or contraindication to dexamethasone
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hasan Sadikin General Hospital

Bandung, West Java, Indonesia, 40161

Actively Recruiting

Loading map...

Research Team

A

Ahmad R Ganiem, M.D., PhD

CONTACT

S

Sofiati Dian, M.D., PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here